Sugi Predict

Sugi Predict / Compounds / SCHEMBL1011900

SCHEMBL1011900

SCHEMBL1011900

COc1cc2c(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)ncnc2cc1O

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 20/20 0.90
▸ RAF1 P04049 9/20 0.90
▸ RIPK2 O43353 1/20 0.90
▸ JAK2 O60674 1/20 0.90
▸ ABL1 P00519 1/20 0.90
▸ EGFR P00533 1/20 0.90
▸ LCK P06239 1/20 0.90
▸ CSF1R P07333 1/20 0.90
▸ LYN P07948 1/20 0.90
▸ RET P07949 1/20 0.90
▸ MET P08581 1/20 0.90
▸ PDGFRB P09619 1/20 0.90
▸ KIT P10721 1/20 0.90
▸ BCR P11274 1/20 0.90
▸ FER P16591 1/20 0.90
▸ FLT1 P17948 1/20 0.90
▸ EPHA2 P29317 1/20 0.90
▸ CYP2C19 P33261 1/20 0.90
▸ KDR P35968 1/20 0.90
▸ MAP2K2 P36507 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013252 0.97 BRAF (0.90) BRAFRAF1RIPK2JAK2ABL1
Cep-32496 SCHEMBL29697285 0.94 BRAF (1.00) BRAFRAF1RIPK2JAK2ABL1
Cep-32496 SCHEMBL1015932 0.94 BRAF (1.00) BRAFRAF1RIPK2JAK2ABL1
Cep-32496 SCHEMBL29351427 0.94 BRAF (1.00) BRAFRAF1RIPK2JAK2ABL1
Cep-32496 SCHEMBL29726019 0.94 BRAF (0.98) BRAFRAF1RIPK2JAK2ABL1
Cep-32496 SCHEMBL18155156 0.94 BRAF (0.98) BRAFRAF1RIPK2JAK2ABL1
SCHEMBL17679303 0.92 BRAF (0.90) BRAFRAF1RIPK2JAK2ABL1
SCHEMBL1010792 0.92 BRAF (1.00) BRAFRAF1RIPK2JAK2ABL1
SCHEMBL16156073 0.91 BRAF (0.93) BRAFRAF1RIPK2JAK2ABL1
SCHEMBL17053430 0.91 BRAF (0.92) BRAFRAF1RIPK2JAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268623-B9 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2018-02-28 — — EP claimed
EP-3147281-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2017-03-29 — — EP claimed
EP-2268623-B1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2015-05-06 — — EP claimed
US-8618289-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-12-31 — — US claimed
JP-2011529021-A — — 2011-12-01 — — JP claimed
US-20110118245-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. 2011-05-19 — — US claimed
EP-2268623-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2011-01-05 — — EP claimed
WO-2009117080-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATON (US) 2009-09-24 — — WO claimed
EP-4223770-A2 NOVEL FUSION MOLECULES AND USES THEREOF Foundation Medicine, Inc. (US) 2023-08-09 — — EP disclosed
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORP. (US) 2018-08-21 — — US disclosed
US-9987281-B2 Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor IGNYTA, INC. (US) 2018-06-05 — — US disclosed
US-9987281-B2 Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor IGNYTA, INC. (US) 2018-06-05 — — US disclosed
EP-2268623-B9 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2018-02-28 — — EP disclosed
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2017-10-19 — — US disclosed
US-8618289-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-12-31 — — US disclosed
US-20110118245-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. 2011-05-19 — — US disclosed
US-20110118245-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. 2011-05-19 — — US disclosed
US-20110118245-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. 2011-05-19 — — US disclosed
EP-2268623-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2011-01-05 — — EP disclosed
WO-2009117080-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATON (US) 2009-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof BRAF, RAF1, ARAF BRAF 1/4885RAF1 2/4885RIPK2 389/4885
US-20110118245-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF BRAF 1/4885RAF1 2/4885RIPK2 529/4885
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF BRAF 1/4885RAF1 2/4885RIPK2 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.